Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors Since 2000, many new treatment options have become available for relapsed and/or refractory multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback